Aplagon has dosed the first patient in HEALING, a Phase 2a study of APAC in chronic limb-threatening ischemia secondary to peripheral arterial occlusive disease. The single- and repeat-dose, IV study in Finland will enroll up to 42 patients across four cohorts, including patients with and without revascularization. Primary objectives are safety and preliminary efficacy signals alongside effects on thrombo-inflammatory biomarkers. The trial follows a 30-participant Phase 1 in healthy volunteers that showed APAC was tolerated with dose-dependent, transient systemic antithrombotic activity. A zirconium-89–labeled APAC PET imaging study in PAOD patients and healthy volunteers is slated to complete in the first half of 2026.
The core move is an early proof-of-concept test for a heparin proteoglycan mimetic that combines anti-platelet, anticoagulant, and anti-inflammatory effects and is designed to bind and persist at vascular injury sites. In CLTI, where first-year mortality approaches 25% and wound healing failures often drive amputation and reinterventions, Aplagon is positioning APAC as an adjunct to procedural care and medical therapy, with in-hospital IV or local administration fitting peri-procedural workflows. The company is also preparing a separate Phase 2 in arteriovenous fistula maturation failure in Europe in 2026, signaling a broader vascular-access and thrombo-inflammation platform strategy.
Strategically, this is an expansion play into a therapeutic gap that sits between procedural innovation and incremental antithrombotic regimens. Restenosis after endovascular treatment remains common—roughly one-third of treated arteries—despite guideline-directed antithrombotics. By combining multi-modal antithrombotic activity with putative lesion targeting, Aplagon is attempting to improve microvascular function, accelerate wound healing, and reduce restenosis without chronic systemic exposure. The 89Zr-PET program is a telling choice: if it confirms lesion localization and retention, it could strengthen the biological rationale, support dose selection, and differentiate APAC from conventional agents viewed primarily through systemic pharmacodynamics.
The central tension is safety and net clinical benefit in a fragile, co-morbid population that is often already on dual antiplatelet therapy and peri-procedural anticoagulation. Any amplification of bleeding risk will be a gating issue for regulators and surgeons, and mechanistic biomarker shifts will not substitute for hard outcomes. The mixed enrollment of patients undergoing revascularization and those managed conservatively increases external relevance but adds heterogeneity that may dilute early efficacy signals. Endpoint selection will matter: time to wound healing, freedom from reintervention, patency, and amputation-free survival are all in play, and a 42-patient study will be powered for signal generation, not outcomes.
For sites, the operational footprint is suited to vascular surgery and angiology services, with short-course IV dosing that can be slotted peri-procedurally and biomarker sampling that will test coordination between cath labs, wards, and research teams. Centers participating in the PET substudy will need radiochemistry and nuclear medicine capacity, narrowing the site pool but potentially elevating data quality. CROs should anticipate tight procedural timing windows, bleeding surveillance, and adjudication needs that mirror antithrombotic device-drug trials. If the signal holds, scale-up will require broader EU and U.S. networks with consistent standards for wound assessment and imaging.
Near term, watch for safety, dose-exposure relationships, and biomarker readouts from HEALING, and for the PET data in the first half of 2026 to validate target engagement. The next design choice—peri-procedural bolus versus short-course post-procedure dosing and how APAC layers on top of dual antiplatelet therapy—will indicate regulatory path and commercial fit. Parallel progress in AVF could de-risk the platform by demonstrating vascular-site targeting in a controlled surgical context. Key risks include bleeding and lack of translation from biomarker and imaging signals to clinically meaningful reductions in reintervention or amputations, along with manufacturing and scale considerations for a proteoglycan mimetic as development broadens beyond Finland.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
